Treatment of Hepatitis C

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Hepatitis C virus (HCV) infects more than 185 million individuals worldwide. Twenty percent of patients chronically infected with HCV progress to cirrhosis. New, simpler therapeutics using direct-acting antivirals that target various stages of the HCV life cycle are in development to eradicate HCV without concomitant interferon.

Related collections

Author and article information

Journal

Title: JAMA

Abbreviated Title: JAMA

Publisher: American Medical Association (AMA)

ISSN (Print): 0098-7484

Publication date Created: August 13 2014

Publication date (Print): August 13 2014

Volume: 312

Issue: 6

Page: 631

Affiliations

[1 ]Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland2Critical Care Medicine Department, Clinical Research Center, National Institutes of

[2 ]Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Article

DOI: 10.1001/jama.2014.7085

PubMed ID: 25117132

SO-VID: 32bf3262-fd9b-409e-931c-5690aee15472

History

Data availability:

Comments

Comment on this article

scite_

Cited by 144

See all cited by

- Version 1

Treatment of Hepatitis C : A Systematic Review

Read this article at